For example, analysis of the generic BRAF inhibitors PLX4720 (progenitor of vemurafenib), SB590885, and CI-1040 reproduced drug sensitivity association with BRAF mutation in melanoma, or afatinib sensitivity with ERBB2 amplifications in breast cancer.3,4,9 These associations between genetic variants and treatment response have helped identify specific patient subpopulations who are most likely to benefit from treatment. The gene discussed is BRAF; the disease is melanoma.